DB-1329
/ DualityBio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
DB-1329: A novel antibody-drug conjugate targeting CDCP1 demonstrates potent preclinical anti-tumor activity across multiple solid tumors
(AACR 2026)
- "These compelling preclinical results establish CDCP1-ADC DB-1329 as a promising therapeutic candidate, with potent and targeted anti-tumor efficacy against multiple CDCP1-positive solid malignancies. Our findings strongly support the continued development and clinical translation of CDCP1-ADC."
ADC • Preclinical • Colon Cancer • Colorectal Cancer • Oncology • Ovarian Cancer • Solid Tumor • CDCP1 • TOP1
1 to 1
Of
1
Go to page
1